Flurazepam - Revision history

JWBE: removed Category:Fluoroarenes; added Category:2-Fluorophenyl compounds using HotCat

2024-09-05T09:17:14Z

removed Category:Fluoroarenes; added Category:2-Fluorophenyl compounds using HotCat

← Previous revision		Revision as of 09:17, 5 September 2024
Line 132:		Line 132:
	[[Category:Sedatives]]		[[Category:Sedatives]]
	[[Category:Chloroarenes]]		[[Category:Chloroarenes]]
	[[Category:~~Fluoroarenes~~]]		[[Category:2-Fluorophenyl compounds]]
	[[Category:Lactams]]		[[Category:Lactams]]
	[[Category:Glycine receptor antagonists]]		[[Category:Glycine receptor antagonists]]

Headbomb: ce

2024-08-02T20:32:10Z

← Previous revision		Revision as of 20:32, 2 August 2024
Line 99:		Line 99:
	Flurazepam is a "classical" benzodiazepine; some other classical benzodiazepines include [[diazepam]], [[clonazepam]], [[oxazepam]], [[lorazepam]], [[nitrazepam]], [[bromazepam]], and [[clorazepate]].<ref>{{cite journal \| vauthors = Braestrup C, Squires RF \| title = Pharmacological characterization of benzodiazepine receptors in the brain \| journal = European Journal of Pharmacology \| volume = 48 \| issue = 3 \| pages = 263–270 \| date = April 1978 \| pmid = 639854 \| doi = 10.1016/0014-2999(78)90085-7 }}</ref> Flurazepam generates an [[active metabolite]], [[N-desalkylflurazepam]], with a very long [[elimination half-life]].<ref name="dailymed.nlm.nih.gov" /> Flurazepam could be therefore unsuitable as a sleeping medication for some individuals due to next-day sedation; however, this same effect may also provide next-day anxiety relief. Residual 'hangover' effects after nighttime administration of flurazepam, such as sleepiness, impaired psychomotor and [[cognitive]] functions, may persist into the next day, which may impair the ability of users to drive safely and increase risks of falls and [[hip fractures]].<ref>{{cite journal \| vauthors = Vermeeren A \| title = Residual effects of hypnotics: epidemiology and clinical implications \| journal = CNS Drugs \| volume = 18 \| issue = 5 \| pages = 297–328 \| year = 2004 \| pmid = 15089115 \| doi = 10.2165/00023210-200418050-00003 \| s2cid = 25592318 }}</ref>		Flurazepam is a "classical" benzodiazepine; some other classical benzodiazepines include [[diazepam]], [[clonazepam]], [[oxazepam]], [[lorazepam]], [[nitrazepam]], [[bromazepam]], and [[clorazepate]].<ref>{{cite journal \| vauthors = Braestrup C, Squires RF \| title = Pharmacological characterization of benzodiazepine receptors in the brain \| journal = European Journal of Pharmacology \| volume = 48 \| issue = 3 \| pages = 263–270 \| date = April 1978 \| pmid = 639854 \| doi = 10.1016/0014-2999(78)90085-7 }}</ref> Flurazepam generates an [[active metabolite]], [[N-desalkylflurazepam]], with a very long [[elimination half-life]].<ref name="dailymed.nlm.nih.gov" /> Flurazepam could be therefore unsuitable as a sleeping medication for some individuals due to next-day sedation; however, this same effect may also provide next-day anxiety relief. Residual 'hangover' effects after nighttime administration of flurazepam, such as sleepiness, impaired psychomotor and [[cognitive]] functions, may persist into the next day, which may impair the ability of users to drive safely and increase risks of falls and [[hip fractures]].<ref>{{cite journal \| vauthors = Vermeeren A \| title = Residual effects of hypnotics: epidemiology and clinical implications \| journal = CNS Drugs \| volume = 18 \| issue = 5 \| pages = 297–328 \| year = 2004 \| pmid = 15089115 \| doi = 10.2165/00023210-200418050-00003 \| s2cid = 25592318 }}</ref>

	Flurazepam is [[lipophilic]], is metabolized hepatically via oxidative pathways. The main pharmacological effect of flurazepam is to increase the effect of GABA at the GABA<sub>A</sub> receptor via binding to the benzodiazepine site on the GABA<sub>A</sub> receptor causing an increase influx of chloride ions into the GABA<sub>A</sub> neuron.<ref>{{cite journal \| vauthors = Oelschläger H \| title = [Chemical and pharmacologic aspects of benzodiazepines] \| journal = Schweizerische Rundschau ~~Fur~~ Medizin Praxis ~~= Revue Suisse de Medecine Praxis~~ \| volume = 78 \| issue = 27–28 \| pages = 766–772 \| date = July 1989 \| pmid = 2570451 }}</ref><ref>{{cite journal \| vauthors = Lehoullier PF, Ticku MK \| title = Benzodiazepine and beta-carboline modulation of GABA-stimulated 36Cl-influx in cultured spinal cord neurons \| journal = European Journal of Pharmacology \| volume = 135 \| issue = 2 \| pages = 235–238 \| date = March 1987 \| pmid = 3034628 \| doi = 10.1016/0014-2999(87)90617-0 }}</ref>		Flurazepam is [[lipophilic]], is metabolized hepatically via oxidative pathways. The main pharmacological effect of flurazepam is to increase the effect of GABA at the GABA<sub>A</sub> receptor via binding to the benzodiazepine site on the GABA<sub>A</sub> receptor causing an increase influx of chloride ions into the GABA<sub>A</sub> neuron.<ref>{{cite journal \| vauthors = Oelschläger H \| title = [Chemical and pharmacologic aspects of benzodiazepines] \| journal = Schweizerische Rundschau für Medizin Praxis \| volume = 78 \| issue = 27–28 \| pages = 766–772 \| date = July 1989 \| pmid = 2570451 }}</ref><ref>{{cite journal \| vauthors = Lehoullier PF, Ticku MK \| title = Benzodiazepine and beta-carboline modulation of GABA-stimulated 36Cl-influx in cultured spinal cord neurons \| journal = European Journal of Pharmacology \| volume = 135 \| issue = 2 \| pages = 235–238 \| date = March 1987 \| pmid = 3034628 \| doi = 10.1016/0014-2999(87)90617-0 }}</ref>

	Flurazepam is contraindicated in pregnancy. It is recommended to withdraw flurazepam during breast feeding, as flurazepam is excreted in [[breast milk]].<ref>{{cite journal \| vauthors = Olive G, Dreux C \| title = [Pharmacologic bases of use of benzodiazepines in peréinatal medicine] \| journal = Archives Françaises de Pédiatrie \| volume = 34 \| issue = 1 \| pages = 74–89 \| date = January 1977 \| pmid = 851373 }}</ref>		Flurazepam is contraindicated in pregnancy. It is recommended to withdraw flurazepam during breast feeding, as flurazepam is excreted in [[breast milk]].<ref>{{cite journal \| vauthors = Olive G, Dreux C \| title = [Pharmacologic bases of use of benzodiazepines in peréinatal medicine] \| journal = Archives Françaises de Pédiatrie \| volume = 34 \| issue = 1 \| pages = 74–89 \| date = January 1977 \| pmid = 851373 }}</ref>

Telephone Directory: Class

2024-03-22T09:34:16Z

Class

← Previous revision		Revision as of 09:34, 22 March 2024
Line 27:		Line 27:
	\| addiction_liability = Moderate		\| addiction_liability = Moderate
	\| routes_of_administration = [[Oral administration\|By mouth]]		\| routes_of_administration = [[Oral administration\|By mouth]]
			\| class = [[Benzodiazepine]]
	<!--Pharmacokinetic data-->\| bioavailability = 83%		<!--Pharmacokinetic data-->\| bioavailability = 83%
	\| metabolism = [[Liver]]		\| metabolism = [[Liver]]

Yungocdy: https://en.m.wikipedia.org/wiki/File:Drug_danger_and_dependence.svg The information in this content is not false

2024-03-04T01:15:39Z

https://en.m.wikipedia.org/wiki/File:Drug_danger_and_dependence.svg The information in this content is not false

← Previous revision		Revision as of 01:15, 4 March 2024
Line 12:		Line 12:
	\| image2 = Flurazepam3d.png		\| image2 = Flurazepam3d.png
	\| width2 = 140		\| width2 = 140
	<!--Clinical data-->		<!--Clinical data-->\| tradename = Dalmane, Dalmadorm, Fluzepam
	\| tradename = Dalmane, Dalmadorm, Fluzepam
	\| Drugs.com = {{drugs.com\|monograph\|flurazepam-hydrochloride}}		\| Drugs.com = {{drugs.com\|monograph\|flurazepam-hydrochloride}}
	\| MedlinePlus = a682051		\| MedlinePlus = a682051
Line 26:		Line 25:
	\| legal_US = Schedule IV		\| legal_US = Schedule IV
	\| legal_status =		\| legal_status =
			\| addiction_liability = Moderate
	\| routes_of_administration = [[Oral administration\|By mouth]]		\| routes_of_administration = [[Oral administration\|By mouth]]
	<!--Pharmacokinetic data-->		<!--Pharmacokinetic data-->\| bioavailability = 83%
	\| bioavailability = 83%
	\| metabolism = [[Liver]]		\| metabolism = [[Liver]]
	\| metabolites = [[N-desalkylflurazepam\|''N''-desalkylflurazepam]] ([[active metabolite]])		\| metabolites = [[N-desalkylflurazepam\|''N''-desalkylflurazepam]] ([[active metabolite]])
	\| elimination_half-life = 2.3 hours<br /> ''N''-desalkylflurazepam: 47–100 hours		\| elimination_half-life = 2.3 hours<br /> ''N''-desalkylflurazepam: 47–100 hours
	\| excretion = [[Kidney]]		\| excretion = [[Kidney]]
	<!--Identifiers-->		<!--Identifiers-->\| IUPHAR_ligand = 7188
	\| IUPHAR_ligand = 7188
	\| CAS_number_Ref = {{cascite\|correct\|??}}		\| CAS_number_Ref = {{cascite\|correct\|??}}
	\| CAS_number = 17617-23-1		\| CAS_number = 17617-23-1
Line 53:		Line 51:
	\| ChEMBL = 968		\| ChEMBL = 968
	\| PDB_ligand = FL7		\| PDB_ligand = FL7
	<!--Chemical data-->		<!--Chemical data-->\| C = 21
	\| C = ~~21\|~~ H = ~~23\|~~ Cl = 1\| F = 1\| N = 3\| O = 1		\| H = 23
			\| Cl = 1
			\| F = 1
			\| N = 3
			\| O = 1
	\| smiles = FC1=CC=CC=C1C2=NCC(N(CCN(CC)CC)C3=C2C=C(C=C3)Cl)=O		\| smiles = FC1=CC=CC=C1C2=NCC(N(CCN(CC)CC)C3=C2C=C(C=C3)Cl)=O
	\| StdInChI_Ref = {{stdinchicite\|correct\|chemspider}}		\| StdInChI_Ref = {{stdinchicite\|correct\|chemspider}}

Headbomb: ce

2024-03-02T13:18:35Z

← Previous revision		Revision as of 13:18, 2 March 2024
Line 98:		Line 98:
	Flurazepam is [[lipophilic]], is metabolized hepatically via oxidative pathways. The main pharmacological effect of flurazepam is to increase the effect of GABA at the GABA<sub>A</sub> receptor via binding to the benzodiazepine site on the GABA<sub>A</sub> receptor causing an increase influx of chloride ions into the GABA<sub>A</sub> neuron.<ref>{{cite journal \| vauthors = Oelschläger H \| title = [Chemical and pharmacologic aspects of benzodiazepines] \| journal = Schweizerische Rundschau Fur Medizin Praxis = Revue Suisse de Medecine Praxis \| volume = 78 \| issue = 27–28 \| pages = 766–772 \| date = July 1989 \| pmid = 2570451 }}</ref><ref>{{cite journal \| vauthors = Lehoullier PF, Ticku MK \| title = Benzodiazepine and beta-carboline modulation of GABA-stimulated 36Cl-influx in cultured spinal cord neurons \| journal = European Journal of Pharmacology \| volume = 135 \| issue = 2 \| pages = 235–238 \| date = March 1987 \| pmid = 3034628 \| doi = 10.1016/0014-2999(87)90617-0 }}</ref>		Flurazepam is [[lipophilic]], is metabolized hepatically via oxidative pathways. The main pharmacological effect of flurazepam is to increase the effect of GABA at the GABA<sub>A</sub> receptor via binding to the benzodiazepine site on the GABA<sub>A</sub> receptor causing an increase influx of chloride ions into the GABA<sub>A</sub> neuron.<ref>{{cite journal \| vauthors = Oelschläger H \| title = [Chemical and pharmacologic aspects of benzodiazepines] \| journal = Schweizerische Rundschau Fur Medizin Praxis = Revue Suisse de Medecine Praxis \| volume = 78 \| issue = 27–28 \| pages = 766–772 \| date = July 1989 \| pmid = 2570451 }}</ref><ref>{{cite journal \| vauthors = Lehoullier PF, Ticku MK \| title = Benzodiazepine and beta-carboline modulation of GABA-stimulated 36Cl-influx in cultured spinal cord neurons \| journal = European Journal of Pharmacology \| volume = 135 \| issue = 2 \| pages = 235–238 \| date = March 1987 \| pmid = 3034628 \| doi = 10.1016/0014-2999(87)90617-0 }}</ref>

	Flurazepam is contraindicated in pregnancy. It is recommended to withdraw flurazepam during breast feeding, as flurazepam is excreted in [[breast milk]].<ref>{{cite journal \| vauthors = Olive G, Dreux C \| title = [Pharmacologic bases of use of benzodiazepines in peréinatal medicine] \| journal = Archives ~~Francaises~~ de ~~Pediatrie~~ \| volume = 34 \| issue = 1 \| pages = 74–89 \| date = January 1977 \| pmid = 851373 }}</ref>		Flurazepam is contraindicated in pregnancy. It is recommended to withdraw flurazepam during breast feeding, as flurazepam is excreted in [[breast milk]].<ref>{{cite journal \| vauthors = Olive G, Dreux C \| title = [Pharmacologic bases of use of benzodiazepines in peréinatal medicine] \| journal = Archives Françaises de Pédiatrie \| volume = 34 \| issue = 1 \| pages = 74–89 \| date = January 1977 \| pmid = 851373 }}</ref>

	== Misuse ==		== Misuse ==

SalomeCzapiewski: wording changed + wiki link added

2024-01-18T05:33:41Z

wording changed + wiki link added

← Previous revision		Revision as of 05:33, 18 January 2024
Line 65:		Line 65:
	'''Flurazepam'''<ref>{{cite patent \| country = BE \| number = 629005}}</ref> (marketed under the brand names '''Dalmane''' and '''Dalmadorm''') is a drug which is a [[benzodiazepine]] derivative. It possesses [[anxiolytic]], [[anticonvulsant]], [[hypnotic]], [[sedative]] and [[skeletal muscle relaxant]] properties. It produces a metabolite with a long [[half-life]], which may stay in the bloodstream for days.<ref name="dailymed.nlm.nih.gov">{{Cite web\|url=https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=8226\|title=FLURAZEPAM HCl CAPSULES, USP\|website=dailymed.nlm.nih.gov}}</ref>		'''Flurazepam'''<ref>{{cite patent \| country = BE \| number = 629005}}</ref> (marketed under the brand names '''Dalmane''' and '''Dalmadorm''') is a drug which is a [[benzodiazepine]] derivative. It possesses [[anxiolytic]], [[anticonvulsant]], [[hypnotic]], [[sedative]] and [[skeletal muscle relaxant]] properties. It produces a metabolite with a long [[half-life]], which may stay in the bloodstream for days.<ref name="dailymed.nlm.nih.gov">{{Cite web\|url=https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=8226\|title=FLURAZEPAM HCl CAPSULES, USP\|website=dailymed.nlm.nih.gov}}</ref>
	<!-- History, society and culture -->		<!-- History, society and culture -->
	Flurazepam was patented in 1968 and came into medical use the same year.<ref name=Fis2006>{{cite book \| vauthors = Fischer J, Ganellin CR \|title=Analogue-based Drug Discovery \|date=2006 \|publisher=John Wiley & Sons \|isbn=9783527607495 \|page=538 \|url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA538 \|language=en}}</ref> Flurazepam, developed by Roche Pharmaceuticals, was one of the first ~~benzo~~ ~~hypnotics~~ ~~(sleeping pills)~~ to be marketed.<ref>{{cite book\| vauthors = Shorter E \|title=A Historical Dictionary of Psychiatry \|date=2005 \|publisher=Oxford University Press \|isbn=978-0-19-029201-0\|chapter-url=https://books.google.com/books?id=juAJCAAAQBAJ&pg=PT66 \|chapter=B}}</ref>		Flurazepam was patented in 1968 and came into medical use the same year.<ref name=Fis2006>{{cite book \| vauthors = Fischer J, Ganellin CR \|title=Analogue-based Drug Discovery \|date=2006 \|publisher=John Wiley & Sons \|isbn=9783527607495 \|page=538 \|url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA538 \|language=en}}</ref> Flurazepam, developed by Roche Pharmaceuticals, was one of the first benzodiazepine [[hypnotic\|hypnotic medications]] to be marketed.<ref>{{cite book\| vauthors = Shorter E \|title=A Historical Dictionary of Psychiatry \|date=2005 \|publisher=Oxford University Press \|isbn=978-0-19-029201-0\|chapter-url=https://books.google.com/books?id=juAJCAAAQBAJ&pg=PT66 \|chapter=B}}</ref>

	== Medical uses ==		== Medical uses ==

DocWatson42: /* Medical uses */Made three minor corrections.

2024-01-16T10:54:29Z

Medical uses: Made three minor corrections.

← Previous revision		Revision as of 10:54, 16 January 2024
Line 69:		Line 69:
	== Medical uses ==		== Medical uses ==
	[[File:Dalmane15mg.jpg\|thumb\|Two Dalmane (flurazepam) [[Capsule (pharmacy)\|capsules]]]]		[[File:Dalmane15mg.jpg\|thumb\|Two Dalmane (flurazepam) [[Capsule (pharmacy)\|capsules]]]]

	Flurazepam is officially indicated for mild to moderate insomnia and as such it is used for short-term treatment of patients with mild to moderate [[insomnia]] such as difficulty falling asleep, frequent awakening, early awakenings or a combination of each. Flurazepam is a long-acting benzodiazepine and is sometimes used in patients who have difficulty in maintaining sleep, though benzodiazepines with intermediate half-lives such as [[loprazolam]], [[lormetazepam]], and [[temazepam]] are also indicated for patients with difficulty maintaining sleep.		Flurazepam is officially indicated for mild to moderate insomnia and as such it is used for short-term treatment of patients with mild to moderate [[insomnia]] such as difficulty falling asleep, frequent awakening, early awakenings or a combination of each. Flurazepam is a long-acting benzodiazepine and is sometimes used in patients who have difficulty in maintaining sleep, though benzodiazepines with intermediate half-lives such as [[loprazolam]], [[lormetazepam]], and [[temazepam]] are also indicated for patients with difficulty maintaining sleep.

	Flurazepam was temporarily unavailable in the United States when its sole producer, Mylan Pharmaceuticals, discontinued making it in January 2019.{{citation needed\|date=October 2019}} In October 2019, the FDA informed pharmacies that they could expect to be resupplied by manufacturers in early to mid December 2019. As of this date{{when\|date=May 2023}}, ~~Flurazepam~~ is now again available in the United States.		Flurazepam was temporarily unavailable in the United States when its sole producer, Mylan Pharmaceuticals, discontinued making it in January 2019.{{citation needed\|date=October 2019}} In October 2019, the FDA informed pharmacies that they could expect to be resupplied by manufacturers in early to mid December 2019. As of this date,{{when\|date=May 2023}} flurazepam is now again available in the United States.

	== Side effects ==		== Side effects ==

DocWatson42: Performed minor cleanup.

2024-01-16T10:52:26Z

Performed minor cleanup.

← Previous revision		Revision as of 10:52, 16 January 2024
Line 65:		Line 65:
	'''Flurazepam'''<ref>{{cite patent \| country = BE \| number = 629005}}</ref> (marketed under the brand names '''Dalmane''' and '''Dalmadorm''') is a drug which is a [[benzodiazepine]] derivative. It possesses [[anxiolytic]], [[anticonvulsant]], [[hypnotic]], [[sedative]] and [[skeletal muscle relaxant]] properties. It produces a metabolite with a long [[half-life]], which may stay in the bloodstream for days.<ref name="dailymed.nlm.nih.gov">{{Cite web\|url=https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=8226\|title=FLURAZEPAM HCl CAPSULES, USP\|website=dailymed.nlm.nih.gov}}</ref>		'''Flurazepam'''<ref>{{cite patent \| country = BE \| number = 629005}}</ref> (marketed under the brand names '''Dalmane''' and '''Dalmadorm''') is a drug which is a [[benzodiazepine]] derivative. It possesses [[anxiolytic]], [[anticonvulsant]], [[hypnotic]], [[sedative]] and [[skeletal muscle relaxant]] properties. It produces a metabolite with a long [[half-life]], which may stay in the bloodstream for days.<ref name="dailymed.nlm.nih.gov">{{Cite web\|url=https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=8226\|title=FLURAZEPAM HCl CAPSULES, USP\|website=dailymed.nlm.nih.gov}}</ref>
	<!-- History, society and culture -->		<!-- History, society and culture -->
	Flurazepam was patented in 1968 and came into medical use the same year.<ref name=Fis2006>{{cite book \| vauthors = Fischer J, Ganellin CR \|title=Analogue-based Drug Discovery \|date=2006 \|publisher=John Wiley & Sons \|isbn=9783527607495 \|page=538 \|url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA538 \|language=en}}</ref> Flurazepam, developed by Roche Pharmaceuticals was one of the first benzo hypnotics (sleeping pills) to be marketed.<ref>{{cite book\| vauthors = Shorter E \|title=A Historical Dictionary of Psychiatry\|date=2005\|publisher=Oxford University Press\|isbn=978-0-19-029201-0\|chapter-url=https://books.google.com/books?id=juAJCAAAQBAJ&pg=PT66\|chapter=B}}</ref>		Flurazepam was patented in 1968 and came into medical use the same year.<ref name=Fis2006>{{cite book \| vauthors = Fischer J, Ganellin CR \|title=Analogue-based Drug Discovery \|date=2006 \|publisher=John Wiley & Sons \|isbn=9783527607495 \|page=538 \|url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA538 \|language=en}}</ref> Flurazepam, developed by Roche Pharmaceuticals, was one of the first benzo hypnotics (sleeping pills) to be marketed.<ref>{{cite book\| vauthors = Shorter E \|title=A Historical Dictionary of Psychiatry \|date=2005 \|publisher=Oxford University Press \|isbn=978-0-19-029201-0\|chapter-url=https://books.google.com/books?id=juAJCAAAQBAJ&pg=PT66 \|chapter=B}}</ref>

	== Medical uses ==		== Medical uses ==

JJMC89 bot III: Moving :Category:Hoffmann-La Roche brands to :Category:Drugs developed by Hoffmann-La Roche per Wikipedia:Categories for discussion/Log/2023 December 9#Category:AstraZeneca brands

2023-12-20T19:39:33Z

Moving Category:Hoffmann-La Roche brands to Category:Drugs developed by Hoffmann-La Roche per Wikipedia:Categories for discussion/Log/2023 December 9#Category:AstraZeneca brands

← Previous revision		Revision as of 19:39, 20 December 2023
Line 125:		Line 125:
	[[Category:Benzodiazepines]]		[[Category:Benzodiazepines]]
	[[Category:Hypnotics]]		[[Category:Hypnotics]]
	[[Category:Hoffmann-La Roche ~~brands~~]]		[[Category:Drugs developed by Hoffmann-La Roche]]
	[[Category:Sedatives]]		[[Category:Sedatives]]
	[[Category:Chloroarenes]]		[[Category:Chloroarenes]]

Buidhe: Removing from Category:GABAA receptor positive allosteric modulators in subcat using Cat-a-lot

2023-12-07T07:39:47Z

Removing from Category:GABAA receptor positive allosteric modulators in subcat using Cat-a-lot

← Previous revision		Revision as of 07:39, 7 December 2023
Line 130:		Line 130:
	[[Category:Fluoroarenes]]		[[Category:Fluoroarenes]]
	[[Category:Lactams]]		[[Category:Lactams]]
	[[Category:GABAA receptor positive allosteric modulators]]
	[[Category:Glycine receptor antagonists]]		[[Category:Glycine receptor antagonists]]
	[[Category:Diethylamino compounds]]		[[Category:Diethylamino compounds]]

← Previous revision		Revision as of 20:32, 2 August 2024
Line 99:		Line 99:
	Flurazepam is a "classical" benzodiazepine; some other classical benzodiazepines include [[diazepam]], [[clonazepam]], [[oxazepam]], [[lorazepam]], [[nitrazepam]], [[bromazepam]], and [[clorazepate]].<ref>{{cite journal \| vauthors = Braestrup C, Squires RF \| title = Pharmacological characterization of benzodiazepine receptors in the brain \| journal = European Journal of Pharmacology \| volume = 48 \| issue = 3 \| pages = 263–270 \| date = April 1978 \| pmid = 639854 \| doi = 10.1016/0014-2999(78)90085-7 }}</ref> Flurazepam generates an [[active metabolite]], [[N-desalkylflurazepam]], with a very long [[elimination half-life]].<ref name="dailymed.nlm.nih.gov" /> Flurazepam could be therefore unsuitable as a sleeping medication for some individuals due to next-day sedation; however, this same effect may also provide next-day anxiety relief. Residual 'hangover' effects after nighttime administration of flurazepam, such as sleepiness, impaired psychomotor and [[cognitive]] functions, may persist into the next day, which may impair the ability of users to drive safely and increase risks of falls and [[hip fractures]].<ref>{{cite journal \| vauthors = Vermeeren A \| title = Residual effects of hypnotics: epidemiology and clinical implications \| journal = CNS Drugs \| volume = 18 \| issue = 5 \| pages = 297–328 \| year = 2004 \| pmid = 15089115 \| doi = 10.2165/00023210-200418050-00003 \| s2cid = 25592318 }}</ref>		Flurazepam is a "classical" benzodiazepine; some other classical benzodiazepines include [[diazepam]], [[clonazepam]], [[oxazepam]], [[lorazepam]], [[nitrazepam]], [[bromazepam]], and [[clorazepate]].<ref>{{cite journal \| vauthors = Braestrup C, Squires RF \| title = Pharmacological characterization of benzodiazepine receptors in the brain \| journal = European Journal of Pharmacology \| volume = 48 \| issue = 3 \| pages = 263–270 \| date = April 1978 \| pmid = 639854 \| doi = 10.1016/0014-2999(78)90085-7 }}</ref> Flurazepam generates an [[active metabolite]], [[N-desalkylflurazepam]], with a very long [[elimination half-life]].<ref name="dailymed.nlm.nih.gov" /> Flurazepam could be therefore unsuitable as a sleeping medication for some individuals due to next-day sedation; however, this same effect may also provide next-day anxiety relief. Residual 'hangover' effects after nighttime administration of flurazepam, such as sleepiness, impaired psychomotor and [[cognitive]] functions, may persist into the next day, which may impair the ability of users to drive safely and increase risks of falls and [[hip fractures]].<ref>{{cite journal \| vauthors = Vermeeren A \| title = Residual effects of hypnotics: epidemiology and clinical implications \| journal = CNS Drugs \| volume = 18 \| issue = 5 \| pages = 297–328 \| year = 2004 \| pmid = 15089115 \| doi = 10.2165/00023210-200418050-00003 \| s2cid = 25592318 }}</ref>

	Flurazepam is [[lipophilic]], is metabolized hepatically via oxidative pathways. The main pharmacological effect of flurazepam is to increase the effect of GABA at the GABA<sub>A</sub> receptor via binding to the benzodiazepine site on the GABA<sub>A</sub> receptor causing an increase influx of chloride ions into the GABA<sub>A</sub> neuron.<ref>{{cite journal \| vauthors = Oelschläger H \| title = [Chemical and pharmacologic aspects of benzodiazepines] \| journal = Schweizerische Rundschau ~~Fur~~ Medizin Praxis ~~= Revue Suisse de Medecine Praxis~~ \| volume = 78 \| issue = 27–28 \| pages = 766–772 \| date = July 1989 \| pmid = 2570451 }}</ref><ref>{{cite journal \| vauthors = Lehoullier PF, Ticku MK \| title = Benzodiazepine and beta-carboline modulation of GABA-stimulated 36Cl-influx in cultured spinal cord neurons \| journal = European Journal of Pharmacology \| volume = 135 \| issue = 2 \| pages = 235–238 \| date = March 1987 \| pmid = 3034628 \| doi = 10.1016/0014-2999(87)90617-0 }}</ref>		Flurazepam is [[lipophilic]], is metabolized hepatically via oxidative pathways. The main pharmacological effect of flurazepam is to increase the effect of GABA at the GABA<sub>A</sub> receptor via binding to the benzodiazepine site on the GABA<sub>A</sub> receptor causing an increase influx of chloride ions into the GABA<sub>A</sub> neuron.<ref>{{cite journal \| vauthors = Oelschläger H \| title = [Chemical and pharmacologic aspects of benzodiazepines] \| journal = Schweizerische Rundschau für Medizin Praxis \| volume = 78 \| issue = 27–28 \| pages = 766–772 \| date = July 1989 \| pmid = 2570451 }}</ref><ref>{{cite journal \| vauthors = Lehoullier PF, Ticku MK \| title = Benzodiazepine and beta-carboline modulation of GABA-stimulated 36Cl-influx in cultured spinal cord neurons \| journal = European Journal of Pharmacology \| volume = 135 \| issue = 2 \| pages = 235–238 \| date = March 1987 \| pmid = 3034628 \| doi = 10.1016/0014-2999(87)90617-0 }}</ref>

	Flurazepam is contraindicated in pregnancy. It is recommended to withdraw flurazepam during breast feeding, as flurazepam is excreted in [[breast milk]].<ref>{{cite journal \| vauthors = Olive G, Dreux C \| title = [Pharmacologic bases of use of benzodiazepines in peréinatal medicine] \| journal = Archives Françaises de Pédiatrie \| volume = 34 \| issue = 1 \| pages = 74–89 \| date = January 1977 \| pmid = 851373 }}</ref>		Flurazepam is contraindicated in pregnancy. It is recommended to withdraw flurazepam during breast feeding, as flurazepam is excreted in [[breast milk]].<ref>{{cite journal \| vauthors = Olive G, Dreux C \| title = [Pharmacologic bases of use of benzodiazepines in peréinatal medicine] \| journal = Archives Françaises de Pédiatrie \| volume = 34 \| issue = 1 \| pages = 74–89 \| date = January 1977 \| pmid = 851373 }}</ref>